CN105435083A - 一种用于产后抑郁症的胶囊剂 - Google Patents
一种用于产后抑郁症的胶囊剂 Download PDFInfo
- Publication number
- CN105435083A CN105435083A CN201610017004.XA CN201610017004A CN105435083A CN 105435083 A CN105435083 A CN 105435083A CN 201610017004 A CN201610017004 A CN 201610017004A CN 105435083 A CN105435083 A CN 105435083A
- Authority
- CN
- China
- Prior art keywords
- parts
- radix
- capsule
- pericarpium citri
- citri reticulatae
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Withdrawn
Links
- 239000002775 capsule Substances 0.000 title claims abstract description 43
- 201000009916 Postpartum depression Diseases 0.000 title claims abstract description 37
- 239000003814 drug Substances 0.000 claims abstract description 29
- QQILFGKZUJYXGS-UHFFFAOYSA-N Indigo dye Chemical compound C1=CC=C2C(=O)C(C3=C(C4=CC=CC=C4N3)O)=NC2=C1 QQILFGKZUJYXGS-UHFFFAOYSA-N 0.000 claims abstract description 16
- VYQNWZOUAUKGHI-UHFFFAOYSA-N monobenzone Chemical compound C1=CC(O)=CC=C1OCC1=CC=CC=C1 VYQNWZOUAUKGHI-UHFFFAOYSA-N 0.000 claims abstract description 16
- DTGKSKDOIYIVQL-WEDXCCLWSA-N (+)-borneol Chemical compound C1C[C@@]2(C)[C@@H](O)C[C@@H]1C2(C)C DTGKSKDOIYIVQL-WEDXCCLWSA-N 0.000 claims abstract description 15
- 235000012239 silicon dioxide Nutrition 0.000 claims abstract description 15
- 238000002360 preparation method Methods 0.000 claims abstract description 12
- 229940079593 drug Drugs 0.000 claims abstract description 10
- 239000009636 Huang Qi Substances 0.000 claims description 16
- 244000146553 Ceiba pentandra Species 0.000 claims description 15
- 235000003301 Ceiba pentandra Nutrition 0.000 claims description 15
- 241000756943 Codonopsis Species 0.000 claims description 15
- 241001057584 Myrrha Species 0.000 claims description 15
- 241001619461 Poria <basidiomycete fungus> Species 0.000 claims description 15
- 210000000582 semen Anatomy 0.000 claims description 14
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Chemical compound O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 claims description 12
- 239000000706 filtrate Substances 0.000 claims description 8
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 claims description 6
- 229920000168 Microcrystalline cellulose Polymers 0.000 claims description 6
- 229920002472 Starch Polymers 0.000 claims description 6
- 238000002481 ethanol extraction Methods 0.000 claims description 6
- 235000019813 microcrystalline cellulose Nutrition 0.000 claims description 6
- 239000008108 microcrystalline cellulose Substances 0.000 claims description 6
- 229940016286 microcrystalline cellulose Drugs 0.000 claims description 6
- 239000000843 powder Substances 0.000 claims description 6
- 235000019698 starch Nutrition 0.000 claims description 6
- 239000008107 starch Substances 0.000 claims description 6
- 239000000284 extract Substances 0.000 claims description 5
- 230000001476 alcoholic effect Effects 0.000 claims description 3
- 230000006837 decompression Effects 0.000 claims description 3
- 238000001035 drying Methods 0.000 claims description 3
- 239000007788 liquid Substances 0.000 claims description 3
- 238000002156 mixing Methods 0.000 claims description 3
- 238000004064 recycling Methods 0.000 claims description 3
- 239000002893 slag Substances 0.000 claims description 3
- 239000006228 supernatant Substances 0.000 claims description 3
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 claims description 2
- 239000012153 distilled water Substances 0.000 claims description 2
- 239000012535 impurity Substances 0.000 claims description 2
- 239000000047 product Substances 0.000 claims description 2
- 230000000694 effects Effects 0.000 abstract description 15
- 210000002216 heart Anatomy 0.000 abstract description 9
- 238000012360 testing method Methods 0.000 abstract description 7
- 208000001431 Psychomotor Agitation Diseases 0.000 abstract description 3
- 206010038743 Restlessness Diseases 0.000 abstract description 3
- 238000010171 animal model Methods 0.000 abstract description 3
- 230000008901 benefit Effects 0.000 abstract description 3
- 238000005516 engineering process Methods 0.000 abstract description 3
- 210000004185 liver Anatomy 0.000 abstract description 3
- 235000006533 astragalus Nutrition 0.000 abstract 2
- REPVLJRCJUVQFA-UHFFFAOYSA-N (-)-isopinocampheol Natural products C1C(O)C(C)C2C(C)(C)C1C2 REPVLJRCJUVQFA-UHFFFAOYSA-N 0.000 abstract 1
- 244000001632 Acorus gramineus Species 0.000 abstract 1
- 235000013073 Acorus gramineus Nutrition 0.000 abstract 1
- 241001573260 Amomum krervanh Species 0.000 abstract 1
- 241001061264 Astragalus Species 0.000 abstract 1
- 235000010110 Astragalus glycyphyllos Nutrition 0.000 abstract 1
- 241000045403 Astragalus propinquus Species 0.000 abstract 1
- 241000092665 Atractylodes macrocephala Species 0.000 abstract 1
- 235000004480 Bombax malabaricum Nutrition 0.000 abstract 1
- 244000293889 Bombax malabaricum Species 0.000 abstract 1
- 241000007126 Codonopsis pilosula Species 0.000 abstract 1
- 235000006965 Commiphora myrrha Nutrition 0.000 abstract 1
- 240000007311 Commiphora myrrha Species 0.000 abstract 1
- 241000202807 Glycyrrhiza Species 0.000 abstract 1
- 241000244365 Ligusticum sinense Species 0.000 abstract 1
- 235000006679 Mentha X verticillata Nutrition 0.000 abstract 1
- 235000002899 Mentha suaveolens Nutrition 0.000 abstract 1
- 235000001636 Mentha x rotundifolia Nutrition 0.000 abstract 1
- 235000007265 Myrrhis odorata Nutrition 0.000 abstract 1
- 208000022873 Ocular disease Diseases 0.000 abstract 1
- 235000008599 Poria cocos Nutrition 0.000 abstract 1
- 244000197580 Poria cocos Species 0.000 abstract 1
- 235000003713 Rhodiola rosea Nutrition 0.000 abstract 1
- 244000042430 Rhodiola rosea Species 0.000 abstract 1
- 229940116229 borneol Drugs 0.000 abstract 1
- CKDOCTFBFTVPSN-UHFFFAOYSA-N borneol Natural products C1CC2(C)C(C)CC1C2(C)C CKDOCTFBFTVPSN-UHFFFAOYSA-N 0.000 abstract 1
- DTGKSKDOIYIVQL-UHFFFAOYSA-N dl-isoborneol Natural products C1CC2(C)C(O)CC1C2(C)C DTGKSKDOIYIVQL-UHFFFAOYSA-N 0.000 abstract 1
- 208000021245 head disease Diseases 0.000 abstract 1
- 238000009776 industrial production Methods 0.000 abstract 1
- LTINPJMVDKPJJI-UHFFFAOYSA-N iodinated glycerol Chemical compound CC(I)C1OCC(CO)O1 LTINPJMVDKPJJI-UHFFFAOYSA-N 0.000 abstract 1
- 238000010792 warming Methods 0.000 abstract 1
- 241000699670 Mus sp. Species 0.000 description 11
- GIYXAJPCNFJEHY-UHFFFAOYSA-N N-methyl-3-phenyl-3-[4-(trifluoromethyl)phenoxy]-1-propanamine hydrochloride (1:1) Chemical group Cl.C=1C=CC=CC=1C(CCNC)OC1=CC=C(C(F)(F)F)C=C1 GIYXAJPCNFJEHY-UHFFFAOYSA-N 0.000 description 11
- 208000024891 symptom Diseases 0.000 description 10
- 230000037396 body weight Effects 0.000 description 8
- 208000013738 Sleep Initiation and Maintenance disease Diseases 0.000 description 7
- 230000000994 depressogenic effect Effects 0.000 description 7
- 206010022437 insomnia Diseases 0.000 description 7
- 239000002994 raw material Substances 0.000 description 7
- 229930006000 Sucrose Natural products 0.000 description 6
- CZMRCDWAGMRECN-UGDNZRGBSA-N Sucrose Chemical compound O[C@H]1[C@H](O)[C@@H](CO)O[C@@]1(CO)O[C@@H]1[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O1 CZMRCDWAGMRECN-UGDNZRGBSA-N 0.000 description 6
- 230000008451 emotion Effects 0.000 description 6
- 239000005720 sucrose Substances 0.000 description 6
- 241000700159 Rattus Species 0.000 description 5
- 239000008280 blood Substances 0.000 description 5
- 210000004369 blood Anatomy 0.000 description 5
- 230000008859 change Effects 0.000 description 5
- 230000003203 everyday effect Effects 0.000 description 5
- 230000036651 mood Effects 0.000 description 5
- 230000001225 therapeutic effect Effects 0.000 description 5
- 230000007812 deficiency Effects 0.000 description 4
- 230000036541 health Effects 0.000 description 4
- 206010025482 malaise Diseases 0.000 description 4
- 239000000203 mixture Substances 0.000 description 4
- 239000000243 solution Substances 0.000 description 4
- 208000019901 Anxiety disease Diseases 0.000 description 3
- 206010012735 Diarrhoea Diseases 0.000 description 3
- 206010041349 Somnolence Diseases 0.000 description 3
- 230000009471 action Effects 0.000 description 3
- 230000036506 anxiety Effects 0.000 description 3
- 239000003651 drinking water Substances 0.000 description 3
- 235000020188 drinking water Nutrition 0.000 description 3
- 235000008216 herbs Nutrition 0.000 description 3
- 238000002347 injection Methods 0.000 description 3
- 239000007924 injection Substances 0.000 description 3
- 210000003734 kidney Anatomy 0.000 description 3
- 238000007086 side reaction Methods 0.000 description 3
- VOXZDWNPVJITMN-ZBRFXRBCSA-N 17β-estradiol Chemical compound OC1=CC=C2[C@H]3CC[C@](C)([C@H](CC4)O)[C@@H]4[C@@H]3CCC2=C1 VOXZDWNPVJITMN-ZBRFXRBCSA-N 0.000 description 2
- 206010014080 Ecchymosis Diseases 0.000 description 2
- 208000027534 Emotional disease Diseases 0.000 description 2
- 206010024264 Lethargy Diseases 0.000 description 2
- 241000699666 Mus <mouse, genus> Species 0.000 description 2
- RJKFOVLPORLFTN-LEKSSAKUSA-N Progesterone Chemical compound C1CC2=CC(=O)CC[C@]2(C)[C@@H]2[C@@H]1[C@@H]1CC[C@H](C(=O)C)[C@@]1(C)CC2 RJKFOVLPORLFTN-LEKSSAKUSA-N 0.000 description 2
- 208000022531 anorexia Diseases 0.000 description 2
- 210000004556 brain Anatomy 0.000 description 2
- 206010061428 decreased appetite Diseases 0.000 description 2
- 238000003745 diagnosis Methods 0.000 description 2
- 230000037213 diet Effects 0.000 description 2
- 235000005911 diet Nutrition 0.000 description 2
- 229960005309 estradiol Drugs 0.000 description 2
- 229930182833 estradiol Natural products 0.000 description 2
- 238000002474 experimental method Methods 0.000 description 2
- 229960000389 fluoxetine hydrochloride Drugs 0.000 description 2
- 229940074869 marquis Drugs 0.000 description 2
- 238000002483 medication Methods 0.000 description 2
- 230000003340 mental effect Effects 0.000 description 2
- 238000000034 method Methods 0.000 description 2
- 230000002611 ovarian Effects 0.000 description 2
- 210000001672 ovary Anatomy 0.000 description 2
- VBUNOIXRZNJNAD-UHFFFAOYSA-N ponazuril Chemical compound CC1=CC(N2C(N(C)C(=O)NC2=O)=O)=CC=C1OC1=CC=C(S(=O)(=O)C(F)(F)F)C=C1 VBUNOIXRZNJNAD-UHFFFAOYSA-N 0.000 description 2
- 230000035935 pregnancy Effects 0.000 description 2
- 238000011084 recovery Methods 0.000 description 2
- 208000037921 secondary disease Diseases 0.000 description 2
- 230000003860 sleep quality Effects 0.000 description 2
- 210000000952 spleen Anatomy 0.000 description 2
- 239000000725 suspension Substances 0.000 description 2
- 238000002560 therapeutic procedure Methods 0.000 description 2
- 206010054196 Affect lability Diseases 0.000 description 1
- 208000031648 Body Weight Changes Diseases 0.000 description 1
- 206010010144 Completed suicide Diseases 0.000 description 1
- 208000020401 Depressive disease Diseases 0.000 description 1
- 241001529793 Dipsas Species 0.000 description 1
- 208000007590 Disorders of Excessive Somnolence Diseases 0.000 description 1
- 206010014357 Electric shock Diseases 0.000 description 1
- 206010020741 Hyperpyrexia Diseases 0.000 description 1
- 206010049976 Impatience Diseases 0.000 description 1
- 241000219000 Populus Species 0.000 description 1
- 101001093925 Rattus norvegicus SEC14-like protein 2 Proteins 0.000 description 1
- 206010041956 Stasis syndrome Diseases 0.000 description 1
- 206010042458 Suicidal ideation Diseases 0.000 description 1
- 208000019790 abdominal distention Diseases 0.000 description 1
- 210000000577 adipose tissue Anatomy 0.000 description 1
- 210000001367 artery Anatomy 0.000 description 1
- 235000019606 astringent taste Nutrition 0.000 description 1
- 230000002146 bilateral effect Effects 0.000 description 1
- 208000005634 blind loop syndrome Diseases 0.000 description 1
- 238000009534 blood test Methods 0.000 description 1
- 230000004579 body weight change Effects 0.000 description 1
- 235000021152 breakfast Nutrition 0.000 description 1
- 230000035568 catharsis Effects 0.000 description 1
- 235000009508 confectionery Nutrition 0.000 description 1
- 238000007796 conventional method Methods 0.000 description 1
- 238000011443 conventional therapy Methods 0.000 description 1
- 230000002354 daily effect Effects 0.000 description 1
- 230000007547 defect Effects 0.000 description 1
- 238000011161 development Methods 0.000 description 1
- 230000018109 developmental process Effects 0.000 description 1
- 201000010099 disease Diseases 0.000 description 1
- 208000002173 dizziness Diseases 0.000 description 1
- 230000035622 drinking Effects 0.000 description 1
- 238000001647 drug administration Methods 0.000 description 1
- 238000002651 drug therapy Methods 0.000 description 1
- 238000002635 electroconvulsive therapy Methods 0.000 description 1
- 230000012173 estrus Effects 0.000 description 1
- 210000003754 fetus Anatomy 0.000 description 1
- 235000013305 food Nutrition 0.000 description 1
- 230000005714 functional activity Effects 0.000 description 1
- 238000003304 gavage Methods 0.000 description 1
- PCHJSUWPFVWCPO-UHFFFAOYSA-N gold Chemical compound [Au] PCHJSUWPFVWCPO-UHFFFAOYSA-N 0.000 description 1
- 239000010931 gold Substances 0.000 description 1
- 229910052737 gold Inorganic materials 0.000 description 1
- 239000000745 gonadal hormone Substances 0.000 description 1
- 230000009931 harmful effect Effects 0.000 description 1
- 206010020765 hypersomnia Diseases 0.000 description 1
- 230000001939 inductive effect Effects 0.000 description 1
- 230000001788 irregular Effects 0.000 description 1
- 230000003907 kidney function Effects 0.000 description 1
- 230000003908 liver function Effects 0.000 description 1
- 210000004072 lung Anatomy 0.000 description 1
- 238000004519 manufacturing process Methods 0.000 description 1
- 235000013336 milk Nutrition 0.000 description 1
- 239000008267 milk Substances 0.000 description 1
- 210000004080 milk Anatomy 0.000 description 1
- YHXISWVBGDMDLQ-UHFFFAOYSA-N moclobemide Chemical compound C1=CC(Cl)=CC=C1C(=O)NCCN1CCOCC1 YHXISWVBGDMDLQ-UHFFFAOYSA-N 0.000 description 1
- 229960004644 moclobemide Drugs 0.000 description 1
- 231100000957 no side effect Toxicity 0.000 description 1
- 210000000056 organ Anatomy 0.000 description 1
- 230000000144 pharmacologic effect Effects 0.000 description 1
- 230000008092 positive effect Effects 0.000 description 1
- 238000004321 preservation Methods 0.000 description 1
- 239000000186 progesterone Substances 0.000 description 1
- 229960003387 progesterone Drugs 0.000 description 1
- 208000020016 psychiatric disease Diseases 0.000 description 1
- 238000001671 psychotherapy Methods 0.000 description 1
- 230000003014 reinforcing effect Effects 0.000 description 1
- 238000002271 resection Methods 0.000 description 1
- 230000028327 secretion Effects 0.000 description 1
- 230000000697 serotonin reuptake Effects 0.000 description 1
- 208000019116 sleep disease Diseases 0.000 description 1
- 208000020685 sleep-wake disease Diseases 0.000 description 1
- GOLXNESZZPUPJE-UHFFFAOYSA-N spiromesifen Chemical compound CC1=CC(C)=CC(C)=C1C(C(O1)=O)=C(OC(=O)CC(C)(C)C)C11CCCC1 GOLXNESZZPUPJE-UHFFFAOYSA-N 0.000 description 1
- 230000009897 systematic effect Effects 0.000 description 1
- 231100000331 toxic Toxicity 0.000 description 1
- 230000002588 toxic effect Effects 0.000 description 1
- 231100000820 toxicity test Toxicity 0.000 description 1
- 230000009466 transformation Effects 0.000 description 1
- 238000002562 urinalysis Methods 0.000 description 1
- 210000001215 vagina Anatomy 0.000 description 1
- 210000003462 vein Anatomy 0.000 description 1
- 210000001835 viscera Anatomy 0.000 description 1
- 239000011800 void material Substances 0.000 description 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
- A61K36/48—Fabaceae or Leguminosae (Pea or Legume family); Caesalpiniaceae; Mimosaceae; Papilionaceae
- A61K36/481—Astragalus (milkvetch)
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/045—Hydroxy compounds, e.g. alcohols; Salts thereof, e.g. alcoholates
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/06—Fungi, e.g. yeasts
- A61K36/07—Basidiomycota, e.g. Cryptococcus
- A61K36/076—Poria
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
- A61K36/19—Acanthaceae (Acanthus family)
- A61K36/195—Strobilanthes
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
- A61K36/23—Apiaceae or Umbelliferae (Carrot family), e.g. dill, chervil, coriander or cumin
- A61K36/236—Ligusticum (licorice-root)
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
- A61K36/28—Asteraceae or Compositae (Aster or Sunflower family), e.g. chamomile, feverfew, yarrow or echinacea
- A61K36/284—Atractylodes
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
- A61K36/31—Brassicaceae or Cruciferae (Mustard family), e.g. broccoli, cabbage or kohlrabi
- A61K36/315—Isatis, e.g. Dyer's woad
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
- A61K36/32—Burseraceae (Frankincense family)
- A61K36/328—Commiphora, e.g. mecca myrrh or balm of Gilead
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
- A61K36/34—Campanulaceae (Bellflower family)
- A61K36/344—Codonopsis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
- A61K36/41—Crassulaceae (Stonecrop family)
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
- A61K36/48—Fabaceae or Leguminosae (Pea or Legume family); Caesalpiniaceae; Mimosaceae; Papilionaceae
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
- A61K36/48—Fabaceae or Leguminosae (Pea or Legume family); Caesalpiniaceae; Mimosaceae; Papilionaceae
- A61K36/484—Glycyrrhiza (licorice)
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
- A61K36/53—Lamiaceae or Labiatae (Mint family), e.g. thyme, rosemary or lavender
- A61K36/534—Mentha (mint)
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
- A61K36/65—Paeoniaceae (Peony family), e.g. Chinese peony
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
- A61K36/70—Polygonaceae (Buckwheat family), e.g. spineflower or dock
- A61K36/704—Polygonum, e.g. knotweed
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
- A61K36/71—Ranunculaceae (Buttercup family), e.g. larkspur, hepatica, hydrastis, columbine or goldenseal
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
- A61K36/75—Rutaceae (Rue family)
- A61K36/752—Citrus, e.g. lime, orange or lemon
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
- A61K36/75—Rutaceae (Rue family)
- A61K36/754—Evodia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/88—Liliopsida (monocotyledons)
- A61K36/888—Araceae (Arum family), e.g. caladium, calla lily or skunk cabbage
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/88—Liliopsida (monocotyledons)
- A61K36/899—Poaceae or Gramineae (Grass family), e.g. bamboo, corn or sugar cane
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/88—Liliopsida (monocotyledons)
- A61K36/906—Zingiberaceae (Ginger family)
- A61K36/9064—Amomum, e.g. round cardamom
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
- A61K9/4841—Filling excipients; Inactive ingredients
- A61K9/4866—Organic macromolecular compounds
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K2236/00—Isolation or extraction methods of medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicine
- A61K2236/30—Extraction of the material
- A61K2236/33—Extraction of the material involving extraction with hydrophilic solvents, e.g. lower alcohols, esters or ketones
- A61K2236/333—Extraction of the material involving extraction with hydrophilic solvents, e.g. lower alcohols, esters or ketones using mixed solvents, e.g. 70% EtOH
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K2236/00—Isolation or extraction methods of medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicine
- A61K2236/30—Extraction of the material
- A61K2236/39—Complex extraction schemes, e.g. fractionation or repeated extraction steps
Landscapes
- Health & Medical Sciences (AREA)
- Natural Medicines & Medicinal Plants (AREA)
- Life Sciences & Earth Sciences (AREA)
- Public Health (AREA)
- Chemical & Material Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Veterinary Medicine (AREA)
- Epidemiology (AREA)
- Mycology (AREA)
- Engineering & Computer Science (AREA)
- Alternative & Traditional Medicine (AREA)
- Biotechnology (AREA)
- Botany (AREA)
- Medical Informatics (AREA)
- Microbiology (AREA)
- Medicines Containing Plant Substances (AREA)
Abstract
本发明涉及一种用于治疗产后抑郁症的胶囊剂及其用途,组方中含有重量份为:黄芪10-20份、红景天5-15份、党参10-15份、白术5-10份、天竺黄3-10份、沙苑子3-8份、没药2-10份、青黛1-3份、豆蔻4-10份、吴茱萸1-5份、茯苓5-15份、苏木4-11份、冰片3-8份、陈皮5-11份、白芍药5-10份、川穹3-10份、甘草2-8份、木棉10-20份、薄荷8-15份、青皮3-12份、石菖蒲3-10份。本发明的药物胶囊制剂,配方合理,具有疏肝解郁、清心除烦、清利头目、温补固摄的功效,能够有效治疗产后抑郁。药物相互配合去除病因,在动物模型试验和临床试验中发挥较为明显的优势,疗效显著,胶囊剂给药方便,制备工艺简单,操作简单,适合工业化生产,患者易于接受,适合在临床中进一步推广应用。
Description
技术领域
本发明涉及中药治疗领域,具体涉及一种用于治疗产后抑郁症的胶囊剂及其用途。
背景技术
产后抑郁症随着社会的发展以及观念的转变呈逐年上升趋势,中医认为产后抑郁是因为妊娠后血聚下养胎,加之产时失血,至产后血虚更甚,血虚肝失所养,肝气郁结,疏泄失职,或产后伤于七情,情志抑郁,究其原因是由情志所伤,肝气郁结所致,肝失条达所致。产后抑郁症属于中医的情志病范畴,而祖国医学在数千年的医疗实践中,对情志病的治疗积累了丰富的经验,并总结出了有效、安全的中医治疗方法。从临床初步观察来看,中药治疗产后抑郁症疗效较好,对产褥复旧无影响,反而增加母乳量,对婴儿也无明显不良影响,是一种更利于母婴健康的治疗手段。产后抑郁的发生乃由肝气郁结或心、肾亏虚所致。《类经》:“心为五脏六腑之大主,而总统魂魄,统该意志,故忧于心则肺应,思动于心则脾应,恐动于心则肾应,此所以五志唯心使也......情志所伤,虽五脏各有所属,然其所由,则无不从心而发。”产后抑郁多表现为情绪低落,兴趣缺乏,心烦,多为心气亏虚,心神失养。故选用内关、神门补益心气、调补心神”。祖国医学还认为“脑为元神之府”,这与现代医学认为脑是人体思维活动的场所的观点是一致的。产后抑郁与脾肾失调、血气不足等有关。产后抑郁患者的睡眠障碍、言语动作减少或迟缓,多与督脉经气运行不畅有关。
产后抑郁症是女性精神障碍中最为常见的类型,是女性生产之后,由于性激素、社会角色及心理变化所带来的身体、情绪、心理等一系列变化。典型的产后抑郁症是产后6周内发生,可持续整个产褥期,有的甚至持续至幼儿上学前。产后抑郁症的发病率在15%~30%。产后抑郁症通常在6周内发病,可在3~6个月自行恢复,但严重的也可持续1~2年,再次妊娠则有20%~30%的复发率。
目前,现有技术的治疗主要有以下几种:1、心理治疗。2、常规治疗。3、药物治疗。可选用选择性5-羟色胺再摄取抑制,具有毒副作用小,服用简便等特点。4、物理治疗。5、电休克治疗。但是上述治疗方式中,均出现不同程度的嗜睡、腹泻等副作用,中药治疗抑郁症的种类也有不少,但是具有明显效果的却很少,且复发概率较高,对后代会产生不利影响,治疗效果不理想。
发明内容
鉴于现有技术缺陷,本发明经过发明人深入地研究,得到了一种用于治疗产后抑郁症中药处方,对于处方本发明人惊喜的发现,该处方的药剂的效果佳,无毒副作用。
本发明的第一个目的在于,发明人对药物组分的用量进行大量探索性试验,提供了一种治疗小儿肠系膜淋巴结炎的中药处方,处方包括的原材料包括:黄芪、红景天、党参、白术、天竺黄、沙苑子、没药、青黛、豆蔻、吴茱萸、茯苓、苏木、冰片、陈皮、白芍药、川穹、甘草、木棉、薄荷、青皮、石菖蒲。
处方的各原料用量在本发明的重量份范围都具有较好的疗效,所述的配方以及组份为:黄芪10-20份、红景天5-15份、党参10-15份、白术5-10份、天竺黄3-10份、沙苑子3-8份、没药2-10份、青黛1-3份、豆蔻4-10份、吴茱萸1-5份、茯苓5-15份、苏木4-11份、冰片3-8份、陈皮5-11份、白芍药5-10份、川穹3-10份、甘草2-8份、木棉10-20份、薄荷8-15份、青皮3-12份、石菖蒲3-10份。
对上述的重量份的配方进行优选,达到更好的技术效果,优选的配方为:生大黄30份、黄芪15份、红景天10份、党参13份、白术8份、天竺黄6.5份、沙苑子5.5份、没药6份、青黛2份、豆蔻7份、吴茱萸3.5份、茯苓10份、苏木7.5份、冰片5.5份、陈皮8份、白芍药8份、川穹8份、甘草5份、木棉15份、薄荷10份、青皮8份、石菖蒲6份。
或者:
黄芪14份、红景天9份、党参12份、白术7份、天竺黄5份、沙苑子5份、没药5份、青黛2.5份、豆蔻6份、吴茱萸4.5份、茯苓12份、苏木5份、冰片5份、陈皮5份、白芍药7份、川穹7份、甘草5份、木棉14份、薄荷10份、青皮8份、石菖蒲6份。
上述原料药的药理作用如下:
黄芪:味甘,性温。
归经:归肺、脾经。
功能主治:补气固表,利尿排毒,用于气虚乏力,食少便溏,中气下陷,久泻脱肛,便血崩漏,表虚自汗,气虚水肿,痈疽难溃,久溃不敛,血虚痿黄,内热消渴。
红景天:味甘,性寒。
归经:肺经。
功能主治:补气清肺;益智养心;收涩止血;散瘀消肿。主气虚体弱;病后畏寒;气短乏力;肺热咳嗽;咯血;白带腹泻;跌打损伤;烫火伤;神经症;高原反应
党参:味甘,性平。
归经:归脾、肺经。
功能主治:补中益气,健脾益肺。用于脾肺虚弱,气短心悸,食少便溏,虚喘咳嗽,内热消渴。
白术:味苦,性温。
归经:归脾、胃经。
功能主治:健脾益气,燥湿利水,止汗,安胎。用于脾虚食少,腹胀泄泻,痰饮眩悸,水肿,自汗,胎动不安。
天竺黄:味甘,寒。
归经:归心、肝经。
功能主治:清热豁痰,凉心定惊。用于热病神昏,中风痰迷,小儿痰热惊痫、抽搐、夜啼。
沙苑子:主要用来治疗肾虚腰痛、阳萎遗精、头晕目眩、失眠多梦、白带过多、视力减退等症。
没药:味苦,性平。
主治:主破血,止痛,疗金疮,杖疮,诸恶疮,痔漏,卒下血,目中翳晕肤赤痛。久服舒筋膜,通血脉,固齿牙,长须发。
青黛:味咸,性寒。
归经:归肝经。
功能主治:清热解毒,凉血,定惊。用于温毒发斑,血热吐衄,胸痛咳血,口疮,痄腮,喉痹,小儿惊痫。
豆蔻:味辛,性温。
归经:归脾、胃、大肠经。
功能主治:行气化湿,温中行气,涩肠止泻。
吴茱萸:味辛,性热,有小毒。
归经:归肝、脾、胃、肾经。
功能主治:散寒止痛,降逆止呕,助阳止泻。用于厥阴头痛,寒疝腹痛,寒湿脚气,经行腹痛,脘腹胀痛,呕吐吞酸,五更泄泻,外治口疮;高血压。
茯苓:味甘、性平。
归经:归心、肺、脾、肾经。
功能主治:利水渗湿,健脾宁心,用于水肿尿少,痰饮眩悸,脾虚食少,便溏泄泻,心神不安,惊悸失眠。
苏木:味甘,性平。
归经:归心、肝、脾经。
功能主治:行血祛瘀,消肿止痛。用于经闭痛经,产后瘀阻,胸腹刺痛,外伤肿痛。
冰片:味辛,性寒。
归经:归心、脾、肺经。
功能主治:开窍醒神,清热止痛。用于热病神昏、痉厥,中风痰厥,气郁暴厥,中恶昏迷,目赤,口疮,咽喉肿痛,耳道流脓。
陈皮:味苦,性温,入脾经、胃经、肺经。
功效:理气健脾,健胃养脾,燥湿化痰,治疗脾胃气滞之脘腹胀满或疼痛、消化不良,湿浊阻中之胸闷腹胀、纳呆便溏。
白芍药:味苦,性寒。
归经:归肝、脾经。
功能主治:平肝止痛,养血调经,敛阴止汗。用于头痛眩晕,胁痛,腹痛,四肢挛痛,血虚萎黄,月经不调,自汗,盗汗。
川穹气浓香,味苦、辛归经归肝、胆、心包经用法用量煎服,3~9克功效活血行气,祛风止痛...川穹性温,是妇科常用药品,有活血顺气的作用,但也不能多用
甘草:味甘,性平。
归经:入脾、胃、心、肺经。
功能主治:补中益气,清热解毒,祛痰止咳,缓急止痛。
木棉:味花:甘、淡,凉。树皮、根:微苦,凉。
功能主治:花:清热利湿,解暑。用于肠炎,痢疾,暑天可作凉茶饮用。树皮:祛风除湿,活血消肿。用于风湿痹痛,跌打损伤。根:散结止痛。胃痛,颈淋巴结结核。
薄荷:味,性凉。
归经:归肺、肝经,宣散风热,清头目,透疹,用于风热感冒,风温初起,头痛,目赤,喉痹,口疮,风疹,麻疹,胸胁胀闷。
石菖蒲:味苦,性温。
功能主治:能开心窍,善通气,止遗尿,安胎除烦闷,能治善忘。
青皮:味苦,性温。
归经:归肝、胆、胃经。
功能主治:疏肝破气,消积化滞。用于胸胁胀痛,疝气,乳核,乳痈,食积腹痛。
本发明所述的一种用于治疗产后抑郁症的胶囊剂,所述的胶囊剂主要用于制备治疗产后抑郁症药物中的用途。
本发明所述的一种用于治疗治疗产后抑郁症药物的胶囊剂,制备方法具体为:
(1)取天竺黄、沙苑子、吴茱萸、冰片、薄荷、青皮和石菖蒲杂质洗净,放入容器内,加入8-10倍量的蒸馏水和0.5倍的80%酒精浸泡1小时后,武火煮沸10-30min,文火1-3小时,提取滤液,备用;
(2)取没药、青黛、豆蔻、茯苓、苏木和陈皮再次加入6-8倍量的水和1.5倍的酒精溶液,武火煮沸30分钟,加热煮沸回流1-2小时,提取滤液,备用;
(3)取白术、白芍药、川穹和木棉加70%乙醇提取2次,每次1.5小时,合并药液,静置24小时,备用;
(4)取党参、黄芪、红景天和甘草粉碎成细粉和步骤(1)中药渣混合后用适量75%乙醇提取2次,每次1小时,收集提取液,静置24小时,备用;
(5)取步骤(1)和(2)的滤液,减压浓缩至相对密度为1.15的浸膏;取第(3)和(4)步骤中制得的上清液,减压回收乙醇,浓缩至60℃,密度为1.09的浸膏,合并浸膏,干燥后备用;
(6)向浸膏中其重量12.5%的淀粉、微晶纤维素混合物,干燥装入胶囊。
本发明的制备方法中,步骤(5)中的淀粉和微晶纤维素重量用量比为1:1。步骤(6)中压制的胶囊成品的重量为0.6-1.0g/粒。
本发明所述的一种用于治疗产后抑郁症的胶囊剂,与现有技术相比的优点在于:
本发明的药物胶囊制剂,配方合理,具有疏肝解郁、清心除烦、清利头目、温补固摄的功效,能够有效治疗产后抑郁。药物相互配合去除病因,在动物模型试验和临床试验中发挥较为明显的优势,疗效显著,胶囊剂给药方便,制备工艺简单,操作简单,适合工业化生产,患者易于接受。
具体实施例
虽然本说明书按照实施方式加以描述,但并非每个实施方式仅包含一个独立的技术方案,说明书的这种叙述方式仅仅是为清楚起见,本领域技术人员应当将说明书作为一个整体,各实施例中的技术方案也可以经适当组合,形成本领域技术人员可以理解的其他实施方式。
实施例1:一种用于治疗产后抑郁症的胶囊剂,含有以下重量份原料:
黄芪10份、红景天5份、党参10份、白术5份、天竺黄3份、沙苑子3份、没药2份、青黛1份、豆蔻4份、吴茱萸1份、茯苓5份、苏木4份、冰片3份、陈皮5份、白芍药5份、川穹3份、甘草2份、木棉10份、薄荷8份、青皮3份、石菖蒲3份。
具体制备方法为:
(1)取天竺黄、沙苑子、吴茱萸、冰片、薄荷、青皮和石菖蒲杂质洗净,放入容器内,加入8-10倍量的蒸馏水和0.5倍的80%酒精浸泡1小时后,武火煮沸10-30min,文火1-3小时,提取滤液,备用;
(2)取没药、青黛、豆蔻、茯苓、苏木和陈皮再次加入6-8倍量的水和1.5倍的酒精溶液,武火煮沸30分钟,加热煮沸回流1-2小时,提取滤液,备用;
(3)取白术、白芍药、川穹和木棉加70%乙醇提取2次,每次1.5小时,合并药液,静置24小时,备用;
(4)取党参、黄芪、红景天和甘草粉碎成细粉和步骤(1)中药渣混合后用适量75%乙醇提取2次,每次1小时,收集提取液,静置24小时,备用;
(5)取步骤(1)和(2)的滤液,减压浓缩至相对密度为1.15的浸膏;取第(3)和(4)步骤中制得的上清液,减压回收乙醇,浓缩至60℃,密度为1.09的浸膏,合并浸膏,干燥后备用;
(6)向浸膏中其重量12.5%的淀粉、微晶纤维素混合物(淀粉、微晶纤维素重量用量比为1:1),干燥装入胶囊。
实施例2:一种用于治疗产后抑郁症的胶囊剂,含有以下重量份原料:
黄芪20份、红景天15份、党参15份、白术10份、天竺黄10份、沙苑子8份、没药10份、青黛3份、豆蔻10份、吴茱萸5份、茯苓15份、苏木11份、冰片8份、陈皮11份、白芍药10份、川穹10份、甘草8份、木棉20份、薄荷15份、青皮12份、石菖蒲10份。
制备方法同实施例1。
实施例3:一种用于治疗产后抑郁症的胶囊剂,含有以下重量份原料:
黄芪15份、红景天10份、党参13份、白术8份、天竺黄6.5份、沙苑子5.5份、没药6份、青黛2份、豆蔻7份、吴茱萸3.5份、茯苓10份、苏木7.5份、冰片5.5份、陈皮8份、白芍药8份、川穹8份、甘草5份、木棉15份、薄荷10份、青皮8份、石菖蒲6份。
制备方法同实施例1。
实施例4:一种用于治疗产后抑郁症的胶囊剂,含有以下重量份原料:
黄芪14份、红景天9份、党参12份、白术7份、天竺黄5份、沙苑子5份、没药5份、青黛2.5份、豆蔻6份、吴茱萸4.5份、茯苓12份、苏木5份、冰片5份、陈皮5份、白芍药7份、川穹7份、甘草5份、木棉14份、薄荷10份、青皮8份、石菖蒲6份。
制备方法同实施例1。
实施例5:动物模型试验
5.1、模型建立
健康雌性SD大鼠SPF级.体重200±20g,买来之后饲养一周适应环境,实验小鼠采用一般方法摘除小鼠卵巢(52只),手术对照组(10只),不切除双侧卵巢,仅摘取卵巢周围少许脂肪组织,于卵巢切除手术完成后第2-5天观测小鼠阴道分泌物,剔除发情周期的大鼠。共得到50只合格小鼠,前16天注射雌二醇注射液0.1mL(2.5μg)+黄体酮0.2mL(4mg),后7天注射雌二醇注射液0.1mL(50μg),正常组和假手术组动物16天每日注射芝麻油0.3mL,后7天注射芝麻油0.1mL,。
5.2、分组以及给药
造模结束后小鼠随机分成5组:模型组、盐酸氟西汀组(50mg/kg)、胶囊剂高剂量组(8g/kg)、胶囊剂中剂量组(4g/kg)、胶囊剂低剂量组(2g/kg),每组10只,另取体重所述的胶囊剂按照本发明实施例3制备得到。结果见表1.
5.3、饮食变化
抑郁之后饮食必然受到影响,尤其体现在饮水上面,根据饮水的多少可以反应出小鼠对食物的需求量,通过各组小鼠的饮水变化进而进一步观察各组之间是否具有差异性。发明人为了进一步刺激小鼠的饮水欲,在水中加入适量的蔗糖,配制成1.1%的蔗糖水,以其满足试验要求。实验前禁止喝水24h,与试验之后第1、4周时观测各组小鼠1h内的饮用蔗糖水量,结果如下表2。
表2不同组别小鼠的饮用蔗糖水的情况
组别 | 1周(mL) | 4周(mL) |
正常对照组 | 16.12±6.23 | 16.88±3.69 |
手术对照组 | 16.56±5.33 | 17.12±3.12 |
模型组 | 10.02±6.36## | 5.99±4.12## |
胶囊剂高剂量组 | 10.01±5.12 | 16.32±6.26**¥ |
胶囊剂中剂量组 | 10.23±6.46 | 15.23±5.13** |
胶囊剂低剂量组 | 10.33±5.75 | 14.18±4.78** |
盐酸氟西汀组 | 10.21±4.44 | 14.29±3.73** |
注:
与正常对照组比较,##P<0.01;
与模型对照组比较,*P<0.05,**P<0.01;
与盐酸氟西汀组比较,¥P<0.05。
从表2可以看出,经过23天造模,模型组大鼠24h饮用蔗糖水均明显低于正常对照组(##P<0.01),表明造模成功;在第4周时,盐酸氟西汀组及中药组合物低、中、高三剂量组的饮用蔗糖水均明显高于模型对照组(**P<0.01或者*P<0.05),并且中药组合物高剂量组各组明显高于盐酸氟西汀组(¥P<0.05),二者均具有统计学差异。因此,本发明的中药处方的治疗效果明显优于盐酸氟西汀。
5.4、不同大鼠体重的变化
分别观察小鼠第1周和第4周的体重变化情况。
表3不同组别小鼠的体重的情况
组别 | 1周 | 4周 |
正常对照组 | 283.23±11.10 | 316.36±16.78 |
手术对照组 | 282.01±11.59 | 314.69±17.69 |
模型组 | 261.32±14.02## | 270.39±20.11## |
胶囊剂高剂量组 | 271.46±12.55** | 310.36±18.33**¥¥ |
胶囊剂中剂量组 | 269.33±13.02* | 305.55±17.96**¥ |
±胶囊剂低剂量组 | 266.11±11.24* | 300.01±19.62** |
盐酸氟西汀组 | 270.12±12.36** | 301.96±16.69** |
注:
与正常对照组比较,##P<0.01;
与模型对照组比较,*P<0.05,**P<0.01;
与盐酸氟西汀组比较,¥P<0.05。
从表2可以看出,经过23天造模,模型组大鼠体重明显低于正常对照组(##P<0.01),表明造模成功,手术对照组和正常对照组没有统计学差异,说明手术对体重没有影响;在第1、4周时,盐酸氟西汀组及中药组合物低、中、高三剂量组的体重明显高于模型对照组(**P<0.01或者*P<0.05),并且在第4周时,中药组合物高、中剂量组各组明显高于盐酸氟西汀组(¥P<0.05),二者均具有统计学差异。
实施例6:临床试验
6.1一般资料
2010-2014年本院共收治产后抑郁症患者202例,均为女性,年龄22-37岁,平均年龄28.9岁。
6.2、诊断标准:
西医诊断标准:
根据美国精神病学在《精神疾病的诊断与统计》(1994年)中制定的:西医症状包括:①、情绪抑郁;②、对全部或者多数活动明显缺乏兴趣或愉悦;③、体重显著下降或者增加;④、失眠或者睡眠过度;⑤、精神运动性兴奋或阻滞;⑥、疲劳或乏力;⑦、遇事皆感豪无意义或自罪感;⑧、思维力减退或注意力涣散;⑨、反复出现死亡或自杀的想法。
具备下列症状的5条或5条以上,必须具有1或2条,在产后4周内发病,且持续2周以上,纳入研究对象。
中医诊断标准:
①、瘀血阻滞证:证侯:产后抑郁寡欢,默默不语,失眠多梦,神思恍惚;恶露淋漓日久,色紫暗有块,面色晦暗;舌黯有瘀斑,苔白,脉弦或涩。主证:产后抑郁寡欢,默默不语,失眠多梦,神思恍惚。次症:恶露淋漓日久,色紫暗有块,面色晦暗。舌象:舌黯有瘀斑,苔白。脉象:脉弦或涩。②、气血亏虚证:证侯:产后焦虑,忧郁,心神不宁,常悲伤欲哭,情绪低落,失眠多梦,健忘,精神萎靡;伴神疲乏力,面色萎黄,纳少便溏,脘闷腹胀;舌淡,苔薄白,脉细弱。主证:产后焦虑,忧郁,心神不宁,常悲伤欲哭,情绪低落,失眠多梦,健忘,精神萎靡:次证:神疲乏力,面色萎黄,纳少便溏,头昏眼花。舌象:舌淡,苔薄白。脉象:脉细弱
根据中医理论,在产后4周内发病,且持续2周以上,具备主证及次症一项以上者,结合舌脉即可诊断。
6.3、治疗方法:将202个患者分组,治疗组101人,分成治疗I组和治疗II组,治疗I组:50人,服用本发明药物实施例3胶囊剂,每日2次,一次两粒,早晚分服,十天为一个疗程;
治疗II组:51人,服用本发明药物实施例4胶囊剂,每日2次,一次两粒,早晚分服,十天为一个疗程;
对照组:101人,服用盐酸氟西汀胶囊,每日1次,一次1粒,早餐服用,十天为一个疗程。经2个疗程的治疗后观察结果。
6.4、疗效判断标准:
治愈:临床各种症状完全消失,半年内未复发;
有效:临床症状减轻或缓解;
无效:临床症状未减轻甚至加重。
治疗结果:经2个疗程的治疗,治疗组138例患者中,治愈116例,有效20例,无效2例,治愈率84.05%,总有效率98.60%,治疗过程中,患者未出现副反应;观察组137例患者中,治愈88例,有效32例,无效17例,治愈率62305%,总有效率87.6%,患者出现不同程度的嗜睡现象,以上结果显示,治疗组治愈率和总有效率明显高于对照组。详细结果见表4。
表4治疗组和对照组的治疗效果比较
实施例7:毒性试验
观察组100例小鼠中,每天给予灌胃药物(12g/kg),2周之后,测定血常规、尿常规、便常规、心电图、肝功能、肾功能,均没有明显的变化,服用本发明中药后仅有1例轻度腹泻和1例轻微嗜睡,出现副反应的几率仅为2%,经对症处置副反应消失。
实施例8、典型病例举例
病例1:齐某,女,23岁,山东郯城人。患者生完孩子后,一直担心丈夫不喜欢女孩子,且丈夫一周20多天在外工作,常感觉心情抑郁,出现焦虑、恐惧,睡眠质量非常差,情绪起伏较大的现象,经常大吵大闹,一度出现自杀现象,被确诊为产后抑郁。服用本发明实施例1的胶囊剂,2个疗程后,情绪稳定,继续服用2个疗程,完全治愈。1个月电话随访没有复发。
病例2:潘某,女,25岁,河南南阳人。患者外来务工人员,患者产子后,由于经济压力,情绪极不稳定,心情浮躁,意志消沉对新生的儿子漠不关心,任其哭闹,作息没有规律,睡眠质量极差,被确诊为产后抑郁症。服用本发明实施例3的胶囊剂2个疗程后,与新生儿子的感情浓厚,关怀备至,继续服用2个疗程,完全治愈,1个月电话随访没有复发。
病例3:管某,女,33岁,山东临沂人。患者二次产子后抑郁复发,情绪低落,不关心任何与自己相关的事情,时常感到不耐烦,注意力涣散,甚至有自杀倾向,确诊为产后抑郁,患者采用本发明实施例4的胶囊剂,服用1个疗程后,产后抑郁减轻,失眠、注意力涣散等症状完全消失,心情也逐渐好起来,体质也明显好转,患者继续服用1个疗程,患者产后抑郁现象完全消失,身体状况得到好转,痊愈。1个月电话随访没有复发。
病例4:杨某,女,31岁,辽宁大连人。出现2013年患者一直想要男孩子,但最后生的一千金,心情失落,郁郁寡欢,产后心情极其糟糕,紧张内疚、多疑、情绪不稳定,动作怪异,作息时间不规律,心神不定,注意力无法集中,并伴有意念消极,高烧。被我院确诊为产后抑郁,服用吗氯贝胺一直没有效果,且患者也极不配合,患者采用本发明实施例2的胶囊剂,服用1个疗程后,产后抑郁减轻,失眠、注意力涣散等症状完全消失,心情也逐渐好起来,体质也明显好转,患者继续服用1个疗程,患者产后抑郁现象完全消失,身体状况得到好转,痊愈。1个月电话随访没有复发。
Claims (8)
1.一种用于产后抑郁症的胶囊剂,其特征在于,有以下原料药组成:黄芪、红景天、党参、白术、天竺黄、沙苑子、没药、青黛、豆蔻、吴茱萸、茯苓、苏木、冰片、陈皮、白芍药、川穹、甘草、木棉、薄荷、青皮、石菖蒲。
2.根据权利要求1所述的胶囊剂,其特征在于,由下列重量份的原料药组成:黄芪10-20份、红景天5-15份、党参10-15份、白术5-10份、天竺黄3-10份、沙苑子3-8份、没药2-10份、青黛1-3份、豆蔻4-10份、吴茱萸1-5份、茯苓5-15份、苏木4-11份、冰片3-8份、陈皮5-11份、白芍药5-10份、川穹3-10份、甘草2-8份、木棉10-20份、薄荷8-15份、青皮3-12份、石菖蒲3-10份。
3.根据权利要求1所述的胶囊剂,其特征在于,由下列重量份的原料药组成:黄芪15份、红景天10份、党参13份、白术8份、天竺黄6.5份、沙苑子5.5份、没药6份、青黛2份、豆蔻7份、吴茱萸3.5份、茯苓10份、苏木7.5份、冰片5.5份、陈皮8份、白芍药8份、川穹8份、甘草5份、木棉15份、薄荷10份、青皮8份、石菖蒲6份。
4.根据权利要求1所述的胶囊剂,其特征在于,由下列重量份的原料药组成:黄芪14份、红景天9份、党参12份、白术7份、天竺黄5份、沙苑子5份、没药5份、青黛2.5份、豆蔻6份、吴茱萸4.5份、茯苓12份、苏木5份、冰片5份、陈皮5份、白芍药7份、川穹7份、甘草5份、木棉14份、薄荷10份、青皮8份、石菖蒲6份。
5.一种制备权利要求4所述的胶囊剂的制备方法,其特征在于,具体的步骤为:
(1)取天竺黄、沙苑子、吴茱萸、冰片、薄荷、青皮和石菖蒲杂质洗净,放入容器内,加入8-10倍量的蒸馏水和0.5倍的80%酒精浸泡1小时后,武火煮沸10-30min,文火1-3小时,提取滤液,备用;
(2)取没药、青黛、豆蔻、茯苓、苏木和陈皮再次加入6-8倍量的水和1.5倍的酒精溶液,武火煮沸30分钟,加热煮沸回流1-2小时,提取滤液,备用;
(3)取白术、白芍药、川穹和木棉加70%乙醇提取2次,每次1.5小时,合并药液,静置24小时,备用;
(4)取党参、黄芪、红景天和甘草粉碎成细粉和步骤(1)中药渣混合后用适量75%乙醇提取2次,每次1小时,收集提取液,静置24小时,备用;
(5)取步骤(1)和(2)的滤液,减压浓缩至相对密度为1.15的浸膏;取第(3)和(4)步骤中制得的上清液,减压回收乙醇,浓缩至60℃,密度为1.09的浸膏,合并浸膏,干燥后备用;
(6)向浸膏中其重量12.5%的淀粉、微晶纤维素混合物,干燥装入胶囊。
6.根据权利要求5所述的胶囊剂的制备方法,其特征在于,步骤(6)中的淀粉和微晶纤维素重量用量比为1:1。
7.根据权利要求5所述的胶囊剂的制备方法,其特征在于,步骤(6)所述的胶囊剂成品的重量为0.6-1.0g/粒。
8.根据权利要求1任一项所述的胶囊剂,其特征在于:所述的胶囊剂在制备治疗产后抑郁症药物中的应用。
Priority Applications (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CN201610017004.XA CN105435083A (zh) | 2016-01-12 | 2016-01-12 | 一种用于产后抑郁症的胶囊剂 |
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CN201610017004.XA CN105435083A (zh) | 2016-01-12 | 2016-01-12 | 一种用于产后抑郁症的胶囊剂 |
Publications (1)
Publication Number | Publication Date |
---|---|
CN105435083A true CN105435083A (zh) | 2016-03-30 |
Family
ID=55546006
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
CN201610017004.XA Withdrawn CN105435083A (zh) | 2016-01-12 | 2016-01-12 | 一种用于产后抑郁症的胶囊剂 |
Country Status (1)
Country | Link |
---|---|
CN (1) | CN105435083A (zh) |
Cited By (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN105749162A (zh) * | 2016-04-03 | 2016-07-13 | 刘�英 | 一种用于治疗产后抑郁症的片剂及其用途 |
Citations (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN105169083A (zh) * | 2015-10-25 | 2015-12-23 | 戴礼礼 | 一种治疗产后抑郁症的中药组合物 |
-
2016
- 2016-01-12 CN CN201610017004.XA patent/CN105435083A/zh not_active Withdrawn
Patent Citations (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN105169083A (zh) * | 2015-10-25 | 2015-12-23 | 戴礼礼 | 一种治疗产后抑郁症的中药组合物 |
Non-Patent Citations (1)
Title |
---|
杜辉等: "《酸枣仁汤》", 30 January 2013, 中国医药科技出版社 * |
Cited By (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN105749162A (zh) * | 2016-04-03 | 2016-07-13 | 刘�英 | 一种用于治疗产后抑郁症的片剂及其用途 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
CN102078520B (zh) | 一种治疗神经性头痛的中药制剂及其制备方法 | |
CN104288651A (zh) | 一种治疗产后缺乳的药物及其制备方法 | |
CN104940740A (zh) | 一种治疗多囊卵巢综合征的中药组合物及其制备方法 | |
CN101700336B (zh) | 一种治疗颅脑外伤后遗性头痛的中药制剂及其制备方法 | |
CN103432559B (zh) | 一种治疗血滞型月经减少及痛经的中药组合物及其制备方法和用途 | |
CN105664099A (zh) | 一种温补肾阳的中药组合物及其制备方法 | |
CN101732685A (zh) | 一种针灸用的皮肤表面浸润中药制剂 | |
CN102940745B (zh) | 一种用于治疗眼睑痉挛的丸剂 | |
CN104888152A (zh) | 一种治疗产后抑郁的中药制剂及其制备方法 | |
CN115779064A (zh) | 一种黄芪扶正方及其制剂与应用 | |
CN103394030A (zh) | 一种治疗肝郁脾虚的中药组合物 | |
CN103202964B (zh) | 益脑安神药酒 | |
CN103223137B (zh) | 一种降血糖的中药制剂 | |
CN105435083A (zh) | 一种用于产后抑郁症的胶囊剂 | |
CN105169083A (zh) | 一种治疗产后抑郁症的中药组合物 | |
CN101439150B (zh) | 一种治疗肠炎的中药组合物 | |
CN104800553A (zh) | 一种治疗更年期失眠症的中药组合物及其制备方法 | |
CN104524479A (zh) | 一种治疗经前期综合征的中药组合物及其制备方法 | |
CN110227113A (zh) | 一种治疗勃起早泄的益肾壮阳的中药组合物及其制备方法 | |
CN104383193A (zh) | 一种治疗神经衰弱的中药 | |
CN103736001B (zh) | 一种治疗失眠的中药组合物 | |
CN103212044A (zh) | 一种治疗心血管疾病的中药组合物 | |
CN105012732A (zh) | 一种用于治疗睡眠障碍综合征的中药丸剂及制备方法 | |
CN105412561A (zh) | 一种治疗失眠症的药物 | |
CN103356970A (zh) | 一种治疗乳腺增生的中药组方 |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
C06 | Publication | ||
PB01 | Publication | ||
C10 | Entry into substantive examination | ||
SE01 | Entry into force of request for substantive examination | ||
WW01 | Invention patent application withdrawn after publication |
Application publication date: 20160330 |
|
WW01 | Invention patent application withdrawn after publication |